BCX4430 for the Treatment of SARS-CoV-2

The mysterious coronavirus outbreak in the Chinese city Wuhan, and its fast spread to many other countries, endanger thousands of lives. The pandemic has catalyzed the drug development for the treatment of SARS-CoV-2. With years of experience in the research of nucleoside analogue inhibitors for the treatment of coronavirus, Creative Biolabs is confident in tailoring BCX4430 (galidesivir) validation service for the treatment of SARS-CoV-2 in a reliable and cost-effective manner.

The Mechanism of BCX4430

Nucleoside analog drugs have been highly successful in the treatment of a range of serious or life-threatening viral infections. Nucleoside analogs target fundamental reproductive mechanisms of the viral genome. BCX4430 is an adenosine analog, with substitution of carbon for nitrogen at position 7 on the base and nitrogen for oxygen at position 1 on the ribose ring. Steric and electrostatic interactions and substitutions on the ribose ring can alter the conformation of the sugar, which in turn affect nucleotide incorporation and chain extension by polymerases. A structural change from a furanose in adenosine to an azasugar ring in BCX4430 alters the electrostatic interaction of the ring, and the viral RNA-dependent RNA polymerase is unable to add more than one or two further nucleotides.

BCX4430 Has the Potential to Fight SARS-CoV-2

BCX4430 is a direct-acting antiviral drug under development for the treatment of serious infections from highly pathogenic viruses. This compound targets viral RNA-dependent RNA polymerase, an enzyme critical for the replication of numerous RNA viruses, and causes RNA chain termination after its conversion to the active triphosphate nucleotide form. BCX4430 is active in vitro against many RNA viral pathogens. It has demonstrated that BCX4430 has broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, such as Ebola, MERS-CoV and SARS-CoV, Marburg, Yellow Fever and Zika viruses. In vivo, BCX4430 is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. As a broad-spectrum RNA virus inhibitor, BCX4430 has the potential to fight SARS-CoV-2.

BCX4430 for the Treatment of SARS-CoV-2 in Creative Biolabs

BCX4430 has entered the phase of clinical research and pharmacokinetics study, and is under clinical development for the treatment of Ebola virus infection. As a broad-spectrum inhibitor, BCX4430 has the potential for the treatment of SARS-CoV-2. Creative Biolabs has established a cutting-edge platform for antiviral drug discovery for SARS-CoV-2. Experienced in antiviral drug discovery, Creative Biolabs has perfected our technical pipelines in the validation of BCX4430 for the treatment of SARS-CoV-2. We would like to share our knowledge and passion to promote the advances of science and for a better tomorrow.

Creative Biolabs is fully competent and dedicated to serving as your one-stop BCX4430 validation service provider for the treatment of SARS-CoV-2. We offer high-quality custom services to meet even the most specific requirements. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Taylor, R.; et al. BCX4430–a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of infection and public health. 2016, 9(3):220-6.

For Research Use Only. We do not provide direct services or products for patients.